| Primary |
| Acute Lymphocytic Leukaemia |
19.9% |
| Product Used For Unknown Indication |
12.1% |
| Hodgkin's Disease |
11.9% |
| Ewing's Sarcoma |
7.9% |
| B-cell Lymphoma |
6.8% |
| Diffuse Large B-cell Lymphoma |
6.6% |
| Non-hodgkin's Lymphoma |
6.6% |
| Chemotherapy |
3.5% |
| Neoplasm Malignant |
3.5% |
| Lymphoma |
3.4% |
| Primitive Neuroectodermal Tumour |
3.1% |
| Retinoblastoma |
2.8% |
| Rhabdomyosarcoma |
2.7% |
| T-cell Type Acute Leukaemia |
2.2% |
| Multiple Myeloma |
1.6% |
| Amyloidosis |
1.4% |
| Brain Neoplasm |
1.2% |
| Haematological Malignancy |
1.1% |
| Ganglioneuroblastoma |
0.9% |
| Drug Use For Unknown Indication |
0.8% |
|
| Treatment Related Secondary Malignancy |
12.0% |
| Febrile Neutropenia |
8.8% |
| Stem Cell Transplant |
8.0% |
| Vomiting |
7.2% |
| Colonic Pseudo-obstruction |
5.6% |
| Neuropathy Peripheral |
5.6% |
| Neutropenia |
4.8% |
| Sepsis |
4.8% |
| Hepatitis B |
4.0% |
| Herpes Zoster |
4.0% |
| Myelodysplastic Syndrome |
4.0% |
| Pyrexia |
4.0% |
| Reversible Posterior Leukoencephalopathy Syndrome |
4.0% |
| White Blood Cell Count Decreased |
4.0% |
| Drug Toxicity |
3.2% |
| Myeloid Leukaemia |
3.2% |
| Neutropenic Sepsis |
3.2% |
| Osteonecrosis |
3.2% |
| Respiratory Failure |
3.2% |
| Septic Shock |
3.2% |
|
| Secondary |
| Acute Lymphocytic Leukaemia |
15.0% |
| Diffuse Large B-cell Lymphoma |
13.0% |
| Product Used For Unknown Indication |
11.9% |
| Non-hodgkin's Lymphoma |
10.9% |
| Hodgkin's Disease |
10.0% |
| Drug Use For Unknown Indication |
7.3% |
| B-cell Lymphoma |
6.4% |
| Burkitt's Lymphoma |
3.5% |
| Prophylaxis |
3.1% |
| Lymphoma |
2.9% |
| Lymphocytic Leukaemia |
2.5% |
| Rhabdomyosarcoma |
2.2% |
| B Precursor Type Acute Leukaemia |
2.1% |
| Mantle Cell Lymphoma |
1.8% |
| Adult T-cell Lymphoma/leukaemia |
1.3% |
| Multiple Myeloma |
1.3% |
| Medulloblastoma |
1.2% |
| Neuroblastoma |
1.2% |
| Chemotherapy |
1.2% |
| Ewing's Sarcoma |
1.1% |
|
| Vomiting |
14.0% |
| White Blood Cell Count Decreased |
11.1% |
| Pyrexia |
8.2% |
| Febrile Neutropenia |
7.3% |
| Neutropenia |
6.8% |
| Sepsis |
6.1% |
| Thrombocytopenia |
4.8% |
| Pneumonia |
4.7% |
| Tachycardia |
4.5% |
| Septic Shock |
4.2% |
| Myelodysplastic Syndrome |
3.7% |
| Pneumocystis Jiroveci Pneumonia |
3.6% |
| Respiratory Failure |
3.1% |
| Stomatitis |
2.9% |
| Hyperglycaemia |
2.8% |
| Weight Decreased |
2.7% |
| Fatigue |
2.5% |
| Maternal Exposure During Pregnancy |
2.4% |
| Progressive Multifocal Leukoencephalopathy |
2.2% |
| Renal Failure |
2.2% |
|
| Concomitant |
| Acute Lymphocytic Leukaemia |
15.6% |
| Product Used For Unknown Indication |
13.6% |
| Non-hodgkin's Lymphoma |
8.1% |
| Diffuse Large B-cell Lymphoma |
8.0% |
| Neoplasm Malignant |
6.5% |
| Prophylaxis |
6.4% |
| Infection Prophylaxis |
5.9% |
| Lymphoma |
5.0% |
| Chemotherapy |
4.8% |
| B-cell Lymphoma |
3.9% |
| Drug Use For Unknown Indication |
3.2% |
| Ewing's Sarcoma Recurrent |
3.1% |
| Prophylaxis Against Graft Versus Host Disease |
2.9% |
| Multiple Myeloma |
2.8% |
| Bone Marrow Conditioning Regimen |
2.1% |
| Mantle Cell Lymphoma |
2.0% |
| Chronic Myeloid Leukaemia |
1.9% |
| Prophylaxis Of Nausea And Vomiting |
1.6% |
| Premedication |
1.5% |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive |
1.3% |
|
| Death |
13.9% |
| Febrile Neutropenia |
7.8% |
| White Blood Cell Count Decreased |
7.8% |
| Thrombocytopenia |
6.1% |
| Drug Ineffective |
5.7% |
| Pyrexia |
5.7% |
| Progressive Multifocal Leukoencephalopathy |
4.8% |
| Acute Myeloid Leukaemia |
4.3% |
| Vomiting |
4.3% |
| Bone Marrow Failure |
3.9% |
| Hepatitis B |
3.9% |
| Infection |
3.9% |
| Renal Failure Acute |
3.9% |
| Sepsis |
3.9% |
| White Blood Cell Count Increased |
3.9% |
| Bacterial Sepsis |
3.5% |
| Neutropenia |
3.5% |
| Drug Interaction |
3.0% |
| Hyponatraemia |
3.0% |
| Pneumonia |
3.0% |
|
| Interacting |
| Acute Lymphocytic Leukaemia |
19.0% |
| Diffuse Large B-cell Lymphoma |
19.0% |
| Prophylaxis |
14.8% |
| Lymphoma |
13.9% |
| Neoplasm Malignant |
4.6% |
| Antifungal Prophylaxis |
3.2% |
| Chronic Lymphocytic Leukaemia |
2.8% |
| Epilepsy |
2.8% |
| Infection Prophylaxis |
2.8% |
| Nausea |
2.8% |
| Drug Use For Unknown Indication |
2.3% |
| Ewing's Sarcoma |
2.3% |
| Fungal Infection |
2.3% |
| Hypertension |
2.3% |
| Non-hodgkin's Lymphoma |
2.3% |
| Chemotherapy |
0.9% |
| Febrile Neutropenia |
0.5% |
| Mucormycosis |
0.5% |
| Oral Candidiasis |
0.5% |
| Product Used For Unknown Indication |
0.5% |
|
| Drug Interaction |
23.1% |
| Ileus Paralytic |
20.5% |
| Nausea |
15.4% |
| White Blood Cell Count Decreased |
10.3% |
| Inappropriate Antidiuretic Hormone Secretion |
7.7% |
| Hepatic Steatosis |
5.1% |
| Neuropathy Peripheral |
5.1% |
| Paraesthesia |
5.1% |
| Leukopenia |
2.6% |
| Mucormycosis |
2.6% |
| Peroneal Nerve Palsy |
2.6% |
|
